KA/EN
Register
Medicines reference
Search
Search
Product

Enrocure

Favourites

Enrofloxacin · Teknovet İlaç Sanayi ve Ticaret A.Ş.

1 form: solution. No registration in force in Georgia.

Forms and doses0 of 1 in force in Georgia

Form Dose Frequency Georgia
10%, Solution No label dose in the reference yet - Georgia Expired
Expired on 06 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: ენროკური® 10%
№ 002523, 002550, 002551
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Enrocure 10%, Solution

100 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a dog using exact Teknovet Enrocure 10%
Not rateable
No numerical score assigned
vetman assessment

Enrocure

10%, 100 mg/ml, solution for injection
Assessed clinical scopeDog · Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a dog using exact Teknovet Enrocure 10% · IV,SC
Care settingNo established companion-animal treatment pathway; select an authorised exact dog/cat presentation after diagnosis, culture and susceptibility review
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Expired · № 002523, 002550, 002551 · Verified on 22 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for dogs. Exact Teknovet Enrocure 10% is transparently identified, but its current label covers cattle, sheep and goats only and its Georgian authorisations expired on 2026-10-06. The ready solution contains 100 mg/ml enrofloxacin plus 30 mg/ml n-butanol. Current authorised companion-animal comparators are different products: GB Baytril is 25 mg/ml for dogs/cats, while US Baytril injection is 22.7 mg/ml, dog-only and used as a single IM loading dose. No Enrocure dog/cat dose, PK or bioequivalence bridge, validated dilution, dose-delivery study, local-tolerance/target-animal safety study or clinical outcome evidence was located. Ingredient efficacy and a matching nominal mg/kg number cannot establish this exact presentation’s benefit-risk.

Enrofloxacin has established veterinary antibacterial roles and authorised dog/cat formulations. That supports choosing an exact companion-animal product; it does not validate this expired-market, food-animal 100 mg/ml presentation. Publish no dog/cat dose or numerical product score.

Important safety and use flags

  • Exact-product boundary: current Teknovet Enrocure 10% is a 100 mg/ml cattle/sheep/goat product. Dogs and cats are absent from its target species, indications and regimen.
  • The historical Georgian authorisations expired on 2026-10-06 and the exact product is absent from the current NFA register. Retail availability does not restore authorisation or supply companion-animal evidence.
  • Do not transfer Baytril 25 mg/ml dosing. It is a different, four-fold less concentrated authorised dog/cat product; the shared 30 mg/ml n-butanol preservative and active ingredient do not establish bioequivalence or local tolerance.
  • Do not transfer US Baytril injection dosing. That 22.7 mg/ml dog-only product is used as one IM loading dose followed by tablets; it neither supports cats nor repeated Enrocure IV/SC treatment.
  • No calculator dose is published. A hypothetical 5 mg/kg conversion would be 0.1 ml in a 2 kg cat and 0.2 ml in a 4 kg cat; these figures illustrate dose-delivery risk but do not validate a regimen, syringe choice or improvised dilution.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Use only when culture/susceptibility and infection-site evidence justify them and a lower-category appropriate antimicrobial is unsuitable.
  • Avoid in growing dogs before skeletal maturity because fluoroquinolones can damage weight-bearing articular cartilage. Exact Enrocure canine age limits and target-animal safety are unknown.
  • Do not use against quinolone-resistant organisms. Cross-resistance is extensive; treatment failure requires diagnosis, source-control and susceptibility review, not blind dose escalation.
  • Exact-product dog/cat pregnancy, lactation, organ-disease, injection-site tolerance and repeated-dose safety are not established. Do not infer them from food-animal use or another enrofloxacin formulation.
  • Review interactions before any enrofloxacin use: avoid antagonistic tetracyclines/macrolides/phenicols; theophylline exposure can rise. Do not mix or dilute Enrocure without product-specific compatibility and stability evidence.
Assessment sources
  1. Teknovet Enrocure 10%2026
  2. Enrocure expired GE record2026
  3. Enrocure current GE audit2026
  4. Baytril 25 VMD label2025
  5. FDA Baytril dog injection1990
  6. FDA feline retinal cap2001
  7. EMA AMEG 20252025
  8. ISCAID canine pyoderma 20252025
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a cat using exact Teknovet Enrocure 10%
Not rateable
No numerical score assigned
vetman assessment

Enrocure

10%, 100 mg/ml, solution for injection
Assessed clinical scopeCat · Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a cat using exact Teknovet Enrocure 10% · IV,SC
Care settingNo established companion-animal treatment pathway; select an authorised exact dog/cat presentation after diagnosis, culture and susceptibility review
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Expired · № 002523, 002550, 002551 · Verified on 22 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for cats. Exact Teknovet Enrocure 10% is transparently identified, but its current label covers cattle, sheep and goats only and its Georgian authorisations expired on 2026-10-06. The ready solution contains 100 mg/ml enrofloxacin plus 30 mg/ml n-butanol. Current authorised companion-animal comparators are different products: GB Baytril is 25 mg/ml for dogs/cats, while US Baytril injection is 22.7 mg/ml, dog-only and used as a single IM loading dose. No Enrocure dog/cat dose, PK or bioequivalence bridge, validated dilution, dose-delivery study, local-tolerance/target-animal safety study or clinical outcome evidence was located. Ingredient efficacy and a matching nominal mg/kg number cannot establish this exact presentation’s benefit-risk.

Enrofloxacin has established veterinary antibacterial roles and authorised dog/cat formulations. That supports choosing an exact companion-animal product; it does not validate this expired-market, food-animal 100 mg/ml presentation. Publish no dog/cat dose or numerical product score.

Important safety and use flags

  • Exact-product boundary: current Teknovet Enrocure 10% is a 100 mg/ml cattle/sheep/goat product. Dogs and cats are absent from its target species, indications and regimen.
  • The historical Georgian authorisations expired on 2026-10-06 and the exact product is absent from the current NFA register. Retail availability does not restore authorisation or supply companion-animal evidence.
  • Do not transfer Baytril 25 mg/ml dosing. It is a different, four-fold less concentrated authorised dog/cat product; the shared 30 mg/ml n-butanol preservative and active ingredient do not establish bioequivalence or local tolerance.
  • Do not transfer US Baytril injection dosing. That 22.7 mg/ml dog-only product is used as one IM loading dose followed by tablets; it neither supports cats nor repeated Enrocure IV/SC treatment.
  • No calculator dose is published. A hypothetical 5 mg/kg conversion would be 0.1 ml in a 2 kg cat and 0.2 ml in a 4 kg cat; these figures illustrate dose-delivery risk but do not validate a regimen, syringe choice or improvised dilution.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Use only when culture/susceptibility and infection-site evidence justify them and a lower-category appropriate antimicrobial is unsuitable.
  • Cats have a label- and post-market-supported risk of irreversible retinal degeneration and blindness when the enrofloxacin exposure ceiling is exceeded. Exact Enrocure feline ocular safety and overdose margin are unknown.
  • Do not use against quinolone-resistant organisms. Cross-resistance is extensive; treatment failure requires diagnosis, source-control and susceptibility review, not blind dose escalation.
  • Exact-product dog/cat pregnancy, lactation, organ-disease, injection-site tolerance and repeated-dose safety are not established. Do not infer them from food-animal use or another enrofloxacin formulation.
  • Review interactions before any enrofloxacin use: avoid antagonistic tetracyclines/macrolides/phenicols; theophylline exposure can rise. Do not mix or dilute Enrocure without product-specific compatibility and stability evidence.
Assessment sources
  1. Teknovet Enrocure 10%2026
  2. Enrocure expired GE record2026
  3. Enrocure current GE audit2026
  4. Baytril 25 VMD label2025
  5. FDA Baytril dog injection1990
  6. FDA feline retinal cap2001
  7. EMA AMEG 20252025
  8. ISCAID canine pyoderma 20252025
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Enrofloxacin100 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Subcutaneous
Registration
Georgia Expired
Expired on 06 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: ენროკური® 10%
№ 002523, 002550, 002551
Verified on: 22 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose or route is established for exact Teknovet Enrocure 10%. Its current official label covers cattle, sheep and goats only. Do not transfer the Baytril 25 mg/ml dog/cat 5 mg/kg SC regimen, the US 22.7 mg/ml dog IM loading regimen, or the food-animal 5 mg/kg regimen to this 100 mg/ml presentation. Use an authorised exact companion-animal product.

Enrofloxacin: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical
    Do not use enrofloxacin in animals with epilepsy, seizures, or seizure disorders associated with the central nervous system, because it may stimulate the CNS.
    Sources: VMD SPC · VMD · FDA
  • Critical
    Do not use in animals hypersensitive to the active substance, another fluoroquinolone, or any excipient. Do not use against known quinolone resistance because cross-resistance is extensive. Treat Pseudomonas infections only after susceptibility testing.
    Sources: VMD SPC · VMD
  • Critical (Dog)
    Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age. has not been established
    Sources: VMD · FDA
  • Critical (Cat)
    In rare instances, use of this product in cats has been associated with Retinal Toxicity. Do not exceed 5 mg/kg of body weight per day in cats. from 20 mg/kg Mydriasis, retinal degeneration... loss of vision. Mydriasis may be an indication of impending or existing retinal changes.
    Sources: FDA
  • Critical (Cat)
    Minimum age differs by product. Some labels prohibit use in kittens younger than 8 weeks; others prohibit use below 3 months of age or below 1 kg because of cartilage injury risk. Use the limit stated for the specific product; the most conservative limit is 3 months and 1 kg.
    Sources: FDA
  • Warning
    Elimination may be delayed in animals with pre-existing renal damage. Use with caution in severe renal or hepatic impairment.
    Sources: VMD SPC · VMD
  • Warning
    Use with caution in severe hepatic impairment. Concomitant administration with other hepatically metabolized medicines may reduce clearance of both the quinolone and the other medicine.
    Sources: VMD SPC · VMD · FDA
  • Warning
    The use is not recommended during pregnancy The safety of the veterinary medicinal product has not been established during pregnancy and lactation Safety in breeding or pregnant cats has not been established The veterinary medicinal product may be used safely in pregnant and lactating animals
    Sources: VMD · FDA
  • Warning
    the use is not recommended during lactation may be used safely in pregnant and lactating animals
    Sources: VMD

Known Drug Interactions

  • Major warning Enrofloxacin + Aminophylline
    Theophylline metabolism is inhibited by erythromycin, cimetidine, propranolol, enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Enrofloxacin + Doxycycline
    Do not combine enrofloxacin with antimicrobials that act antagonistically to quinolones, including macrolides, tetracyclines such as doxycycline, and phenicols such as chloramphenicol.
    Recommendation: Do not administer concurrently. Based on susceptibility testing, choose either a bactericidal fluoroquinolone or a bacteriostatic tetracycline.
    Sources: VMD SPC · VMD
  • Major warning Enrofloxacin + Theophylline
    Do not use concurrently with theophylline as the elimination of theophylline may be delayed Concomitant administration of theophylline requires careful monitoring as serum levels of theophylline may increase
    Recommendation: Avoid the combination where possible. If concomitant use is unavoidable, monitor serum theophylline and be prepared to reduce its dose.
    Sources: VMD
  • Minor warning Enrofloxacin + Sucralfate
    The concomitant administration of substances containing magnesium or aluminium may reduce the absorption of enrofloxacin. These drugs should be administered two hours apart.
    Recommendation: Separation is not critical in dogs, but a 2-hour interval is safe and label-consistent. No comparable measurement exists in cats; use a 2-hour interval in cats.
    Sources: VMD SPC · VMD · JVIM

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗